Business Wire

Boca Biolistics is the First CRO to Participate in VERIF.i ® , Scientist.com’s New Supplier Pre-assessment Program

Share

Scientist.com, the pharmaceutical industry’s leading R&D marketplace, announced today that VERIF.i®, the company’s new supplier pre-assessment program, has officially launched with the successful completion of an on-site assessment of Boca Biolistics’s biorepository facilities. VERIF.i was developed to help both sides of the Scientist.com marketplace. Pre-assessments help suppliers such as Boca Biolistics demonstrate their quality and capabilities, while helping pharma and biotech customers select regulated services in an accelerated manner with more confidence and less risk.

“We have always been confident in the quality of our facilities and the personnel that operate them,” stated Joseph Mauro, Chief Vision Officer at Boca Biolistics. “VERIF.i allows us to demonstrate our expertise to current and future clients of Scientist.com’s marketplace as well as to our existing clientele outside of the platform."

Boca Biolistics is a hybrid contract research organization (CRO) with an integrated life science biorepository, offering central laboratory testing as well as clinical trial services. The company procures human biospecimens from around the world for commercial product development and the advancement of precision medicine. VERIF.i enables Boca Biolistics and other suppliers of regulated research services to communicate their standards against pre-defined criteria developed for the biopharma industry and then confirm them through independent, third-party auditors that carry out an on-site inspection.

“On-site assessments are expensive, resource intensive and time consuming for customers and suppliers,” stated Matt McLoughlin, Sr. VP of Categories and Compliance at Scientist.com. “VERIF.i standardizes and simplifies the process for both sides of the market. It enables suppliers to differentiate themselves from their peers while enabling customers to gain valuable, unbiased insight into a supplier’s facilities, personnel and processes."

VERIF.i is an expansion of Scientist.com’s award-winning COMPLi® solution. For more information visit https://www.scientist.com/verifi/

About Boca Biolistics

Boca Biolistics is a hybrid CRO leveraging our vertically integrated model to build a life sciences biorepository with industry leading clinical and molecular data sets. Our commercial biobank has >800,000 specimens available for use in R&D as well as clinical trials. Our CLIA/CAP accredited reference lab offers clinical testing as well as research testing services for diagnostic and pharma. Our CRO division provides end-to-end services for both diagnostic and biopharma clinical trials.

Visit bocabio.com to learn more.

Join us on our LinkedIn page.

About Scientist.com

Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saves time and money, reduces risk and provides access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, over 80 biotechnology companies and the US National Institutes of Health (NIH).

Visit scientist.com to learn more.

Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sean Preci
Director of Communications
+1 858 455-1300 ext. 401
marketing@scientist.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Climate Pledge Announces 86 New Signatories, Including Procter & Gamble, HP, and Salesforce, Signaling Their Commitment to Achieving Net-Zero Carbon by 2040 or Sooner20.9.2021 12:00:00 CEST | Press release

Today, Amazon and Global Optimism announced that more than 200 companieshave now signed The Climate Pledge. The 86 new signatories joining The Climate Pledge include Procter & Gamble, HP, Salesforce, ASOS, and Nespresso. Pledge signatories in total generate over $1.8 trillion in global annual revenues and have more than 7 million employees across 26 industries in 21 countries. By achieving net-zero carbon by 2040, 10 years ahead of the Paris Agreement, current Climate Pledge signatories are expected to collectively mitigate 1.98 billion metric tons (BMT) of carbon emissions from a 2020 baseline. This is equivalent to 5.4% of current global annual emissions—demonstrating the collective impact The Climate Pledge is expected to have in addressing climate change and prompting more action to tackle the climate crisis. Signatories to The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis. Implement decarbonization strategies in line with the Paris Agreeme

AlbaCore Capital Group Continues to Expand with Three Senior Hires20.9.2021 11:20:00 CEST | Press release

European credit specialist AlbaCore Capital Group (“AlbaCore”), today announces three senior hires to reinforce its Operations, Business Development and Investor Relations teams. As part of the growth of the AlbaCore platform, investing across the European credit spectrum with $8.5bn1 AUM, AlbaCore has bolstered its senior executive group. Jenny Fung is appointed as Managing Director of Investor Relations in New York to further expand global investor relationships and our commitment to the region. Tara Mulholland joins as Head of Business Transformation and Micaela Kelley as Deputy Chief Operating Officer to support Matthew Courey, Chief Operating Officer and Founding Partner. Jenny brings a wealth of financial services experience with 25 years in the industry. She joins from Taconic Capital, a global investment firm, where she was Director of Marketing and Investor Relations for 13 years, and prior to that at Bank of America, AIG and CSFB. Tara will oversee an operational change progr

Cedo Reveals Roadmap for Sustainable Business Growth20.9.2021 09:00:00 CEST | Press release

Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/ Cedo CEO, Rik De Vos, says “Cedo is proud of our contribution to achieving the goals of sustainable business development outlined by the UN” (Photo: Business Wire) “Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transf

Coffee Pod Convenience Without the Landfill Guilt: Introducing the Home-Compostable Coffee Capsule, Co-Developed by Jabil and Prosol20.9.2021 08:00:00 CEST | Press release

Jabil Packaging Solutions (JPS), a division of manufacturing solutions provider Jabil Inc. (NYSE: JBL), today announced a significant advancement in coffee pod sustainability with the launch of their home-compostable coffee capsule for single serve espresso brewers. This high-barrier coffee capsule improves on existing solutions by eliminating the need for a plastic or foil pouch that is sometimes required to preserve freshness in compostable coffee capsules. JPS co-developed the compostable coffee capsule with Productos Solubles S.A. (Prosol), a leading European coffee roaster, based in Palencia, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210919005012/en/ Co-developed by Jabil Packaging Solutions and Productos Solubles S.A. (Prosol), the home-compostable coffee capsule improves on existing solutions and is a significant advancement in coffee pod sustainability. (Photo: Business Wire) The technically complex coffe

Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 15:34:00 CEST | Press release

Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w

Ipsen: ESMO 2021: Cabometyx ® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 06:30:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021

Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 20:46:00 CEST | Press release

Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom